CART45RA-NKG2D CELLS
Sponsors
Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz, Hospital Universitario La Paz
Conditions
Central nervous system tumoursRefractory/ relapsed acute lymphoblastic leukemia in childrenSarcomaadolescents and young adults.
Phase 1
A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults with Advanced Sarcoma
RecruitingCTIS2024-513514-35-00
Start: 2024-01-10Target: 18Updated: 2025-12-19
A Phase I Clinical Trial of CART cell therapy for refractory/ relapsed acute lymphoblastic leukemia with unmet needs in children, adolescents and young adults: feasibility and safety study (REALL_CART).
WithdrawnCTIS2023-509723-41-00
Target: 10Updated: 2024-05-07
A Phase I Clinical Trial of CART cell therapy for refractory/ relapsed acute lymphoblastic leukemia with unmet needs in children, adolescents and young adults: feasibility and safety study (REALL_CART).
RecruitingCTIS2023-509723-41-01
Start: 2025-06-16Target: 10Updated: 2025-09-29
Phase I/II clinical trial on the use of central nervous system administrations of CART-NKG2D or NKIL15 cells in children, adolescent and young adults with recurrent/refractory high grade Central Nervous System tumours (CINK-CAR)
Not yet recruitingCTIS2026-525876-24-00
Target: 30Updated: 2026-07-15